Table 1.
Demographics
| Placebo (n=69) | 750mg (n=70) | 1,000mg (n=72) | 2,000mg (n=71) | Total (n=282) | |
|---|---|---|---|---|---|
| Age | |||||
| n | 69 | 70 | 72 | 71 | 282 |
| Mean (SD) | 62 (13) | 58 (11) | 60 (12) | 62 (11) | 60 (12) |
| Race | |||||
| White | 66 (96%) | 64 (91%) | 70 (97%) | 67 (94%) | 267 (95%) |
| Black or African American | 2 (3%) | 3 (4%) | 0 (0%) | 3 (4%) | 8 (3%) |
| Native Hawaiian or other Pacific Islander | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| Asian | 0 (0%) | 1 (1%) | 1 (1%) | 1 (1%) | 3 (1%) |
| American Indian or Alaska Native | 1 (1%) | 1 (1%) | 0 (0%) | 0 (0%) | 2 (1%) |
| Gender | |||||
| Female | 45 (65%) | 46 (66%) | 47 (65%) | 48 (68%) | 186 (66%) |
| Disease stage | |||||
| I/II | 22 (32%) | 21 (30%) | 24 (33%) | 23 (32%) | 90 (32%) |
| III/IV | 44 (64%) | 45 (64%) | 44 (61%) | 42 (59%) | 175 (62%) |
| Unknown | 3 (4%) | 4 (6%) | 4 (6%) | 6 (9%) | 17 (6%) |
| Baseline Fatigue Score | |||||
| 4-7 | 50 (73%) | 50 (71%) | 50 (70%) | 51 (72%) | 201 (71%) |
| 8-10 | 19 (28%) | 20 (29%) | 22 (31%) | 20 (28%) | 81 (29%) |
| Current chemotherapy | |||||
| Yes | 39 (57%) | 39 (56%) | 42 (58%) | 40 (56%) | 160 (57%) |
| Current radiation therapy | |||||
| Yes | 12 (17%) | 12 (17%) | 14 (19%) | 13 (18%) | 51 (18%) |
| Type of cancer | |||||
| Breast | 24 (35%) | 29 (41%) | 26 (36%) | 30 (42%) | 109 (39%) |
| Colon | 7 (10%) | 7 (10%) | 5 (7%) | 10 (14%) | 29 (10%) |
| Lung | 8 (12%) | 8 (11%) | 10 (14%) | 9 (13%) | 35 (12%) |
| Combination/unknown/other | 30 (44%) | 26 (37%) | 31 (43%) | 22 (31%) | 109 (39%) |
| Menopausal status | |||||
| Premenopausal | 7 (10%) | 7 (10%) | 7 (10%) | 6 (9%) | 27 (10%) |
| Postmenopausal | 34 (49%) | 35 (50%) | 37 (51%) | 39 (55%) | 145 (51%) |
| Hysterectomy without oophorectomy | 4 (6%) | 4 (6%) | 3 (4%) | 3 (4%) | 14 (5%) |
| Previous radiation therapy | |||||
| Yes | 23 (50%) | 16 (33%) | 19 (39%) | 14 (30%) | 72 (38%) |
| Previous chemotherapy | |||||
| Yes | 30 (65%) | 32 (67%) | 34 (69%) | 28 (60%) | 124 (65%) |